



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCellenza 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

51st AISF Annual Meeting Rome, February 22nd-23rd, 2018

SCIENTIFIC PROGRAMME

Thursday, February 22nd

08.30-10.00 Selected Oral Communications (Fibrosis, cirrhosis, and portal hypertension clinical)

Chairpersons: S. Piano, Padua
M. Bernardi, Bologna

08.30-08.45 Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

V. Calvaruso, S. Petta, I. Cacciola, G. Cabibbo, F. Cartabellotta, A. Di Rosolini, A. Davì, M. Cannavò, M. Russello, M. Distefano, G. Scifo, F. Di Lorenzo, T. Prestileo, L. La Rocca, A. Montineri, G. Fiduli, A. Digiacomò, M. Cannizzaro, S. Madonia, A. Licata, G. Malizia, G. Alaimo, G. Bertino, B. Cacopardo, C. Iacobello, A. Aversa, L. Guarneri, I. Scalisi, G. Mazzola, L. Mondello, V. Portelli, G. Squadrito, C. Cammà, G. Raimondo, A. Craxì, V. Di Marco on behalf of Unit RESIST-HCV (Rete Sicilia Selezione Terapia - HCV) Palermo, Messina, Modica (RG), Catania, Siracusa, Comiso (RG), Agrigento, Caltanissetta, Enna, Mazara del Vallo (TP), Trapani

08.45-09.00 Endoscopic radiofrequency ablation for the treatment of gastric antral vascular ectasia in cirrhotic patients: a bi-centric clinical and economical cost-effective analysis

M. Senzolo, S. Realdon, B. Simoncin, A. Zanetto, S. Caronna, G. Saracco, C. De Angelis, W. Debernardi-Venon - Padua, Turin

09.00-09.15 Epidemiology, predictors and outcomes of multi drug resistant (MDR) bacterial infections in patients with cirrhosis across the world. Final results of the "Global study"

S. Piano, V. Singh, P. Caraceni, R. Maiwall, C. Alessandria, J. Fernandez, E.C. Soares, D.J. Kim, S.E. Kim, M. Marino, J. Vorobioff, R. Ribeiro Barea, M. Merli, L. Elkrief, V. Vargas, A. Krag, S.P. Singh, L.A. Lesmana, C. Toledo, S. Marciano, X. Verhelst, F. Wong,

N. Intagliata, L. Rabinowich, L.A. Colombato, S.G. Kim, A. Gerbes, F. Durand, J.P. Roblero, K.R. Bhamidimarri, T.D. Boyer, M. Maevskaya, E. Fassio, H.S. Kim, J.S. Hwang, A. Gadano, S.K. Sarin, P. Angeli on behalf of the International Club of Ascites Global Study Group - Padua, Chandigarh (India), Bologna, New Delhi (India), Turin, Barcelona (Spain), Campinas (Brazil), Chuncheon (Republic of Korea), Anyang (Republic of Korea), Buenos Aires (Argentina), Rosario (Argentina), Campo Grande (Brazil), Rome, Geneva (Switzerland), Odense (Denmark), Cuttack (India), Jakarta (Indonesia), Valdivia (Chile), Ghent (Belgium), Toronto (Canada), Charlottesville, (VA, USA), Tel-Aviv (Israel), Bucheon (Republic of Korea), Munich (Germany), Clichy (France), Santiago (Chile), Miami (FL, USA), Tucson (AZ, USA), Moscow (Russia), Seoul (Republic of Korea), Daegu (Korea)

09.15-09.30 Noninvasive Prediction of Esophageal Varices by Liver Stiffness Measurement and Platelet Values in Patients with Liver Cirrhosis due to Nonalcoholic Fatty Liver Disease: A Multicenter Cross-sectional Study

S. Petta, G. Sebastiani, E. Bugianesi, M. Viganò, V.W. Wong, A. Berzigotti, A.L. Fracanzani, Q. Anstee, F. Marra, M. Barbara, V. Calvaruso, C. Cammà, V. Di Marco, R. Lombardi, M.G. Rumi, A. Craxì, V. de Ledinghen - Palermo, Montreal QC (Canada), Turin, Milan, Hong Kong, Bern (Switzerland), Newcastle upon Tyne (UK), Florence, Pessac (France)

09.30-09.45 Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

C. Masetti, R. Lionetti, M. Lupo, M. Siciliano, V. Giannelli, F.R. Ponziani, E. Teti, C. Dell'Unto, S. Francioso, A. Brega,



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- M. Montalbano, U. Visco-Comandini, C. Taibi, G. Galati, U. Vespasiani Gentilucci, A. Picardi, M. Andreoni, M. Pompili, A.M. Pellicelli, G. D'Offizi, A. Gasbarrini, A. De Santis, M. Angelico - *Rome*
- 09.45-10.00 **Gender dimorphism in fibrosis dynamics in a murine model of chronic hepatic injury**
M. Crescenzi, C. Frasson, M.F. Secchi, P. Burra, G. Basso, F.P. Russo - *Padua*
- 10.00-10.30 State-of-the-Art Lecture**
Introduced by: E. Bugianesi, *Turin*
(Mal)nutrition and liver disease
G. Marchesini Reggiani, *Bologna*
- 10.30-11.00 Coffee break and Posters view**
Tutors: M. Gambato, *Padua*
F. Pezzuto, *Naples*
- 11.00-12.15 General Assembly II**
- 12.15-13.15 Selected Oral Communications (Autoimmune & biliary diseases; miscellaneous)**
Chairpersons: M. Carbone, *Milan*
L. Muratori, *Bologna*
- 12.15-12.30 **Outbreak of Acute Hepatitis A involving young men in Lombardy Region, Italy: risk factors, clinical and virological characteristics**
M. Iavarone, M. Viganò, C. Orcese, M. Coen, C. Oggioni, A. Spinetti, A. Soria, C. Galli, C. Tagliacarne, L. Scaramella, M. Merli, R. Rossotti, G. Gubertini, S. Merli, A. Piscitelli, A. Comelli, V. Castelli, D. Cereda, M. Gramegna, M. Puoti, A. Gori, M.G. Rumi, F. Castelli, P. Lampertico, L. Romanò - *Milan, Brescia, Monza*
- 12.30-12.45 **Specific human cholangiocarcinoma (CCA) subpopulations of cancer stem cells (CSCs) express DoubleCortin-Like Kinase 1 (DCLK1) and DCLK1 inhibition induces anti-cancer effects**
L. Nevi, S. Di Matteo, G. Carpino, V. Cardinale, I. Zizzari, V. Ambrosino, D. Costantini, S. Safarikia, E. Manzi, A.M. Derose, F. Melandro, M.C. Bragazzi, G. Grazi, P.B. Berloco, F. Giuliani, E. Gaudio, D. Alvaro - *Rome*
- 12.45-13.00 **Incidence, prevalence and mortality of Primary Sclerosing Cholangitis (PSC) in Italy: a population-based study**
M. Carbone, A. Rocchetti, Y. Kodra, V. Manno, G. Minelli, F. Malinverno, A. Floreani, P. Invernizzi, S. Conti, D. Taruscio
Milan, Rome, Padua
- 13.00-13.15 **Dexamethasone reduces cholestasis-associated oxidative stress and inflammation in bile-duct ligated rats via CAR activation**
D. Gabbia, L. Pozzo, G. Zigiotta, M. Roverso, D. Sacchi, A. Dalla Pozza, S. Bogiagli, M. Guido, A. Floreani, S. De Martin - *Padua, Pisa*
- 13.15-13.45 Young Investigator Lecture**
Introduced by: A. Benedetti, *Ancona*
Stem/progenitor cell niche in liver pathophysiology
V. Cardinale, *Rome*
- 13.45-14.45 Lunch break and Posters view**
Tutors: P. Dongiovanni, *Milan*
F.R. Ponziani, *Rome*
- 14.45-15.30 2016 AISF Fellowships Report**
Introduced by: L. Valenti, *Milan*
- 14.45-15.00 **Cholangiocarcinoma Primary, Circulating and Metastatic Stem-Like Cells: Set up of an Orthotopic Mouse Model**
M. Correnti, *Rozzano*
- 15.00-15.15 **Role of immunosurveillance mechanisms in the occurrence and recurrence of HCC in patients with HCV-related cirrhosis after antiviral therapy with DAAs**
M. Maida, *Palermo*
- 15.15-15.30 **Gene mutations in circulating tumour DNA and exosomal miRNAs expression as biomarkers of early lesion and residual disease in hepatocellular carcinoma patients**
F. Pezzuto, *Naples*
- 15.30-16.00 State-of-the-Art Lecture**
Introduced by: P. Burra, *Padua*
Who is the candidate for liver transplantation in 2018 (and beyond)?
P-A Clavien, *Zurich (Switzerland)*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- 16.00-16.15 Presentation of the AISF prize for the 2 best Italian papers in 2016**
Introduced by: C. Cammà, *Palermo*
G. Raimondo, *Messina*
Basic science
Clinical
- 16.15-16.45 Coffee break and Posters view**
Tutors: M. Gambato, *Padua*
F. Pezzuto, *Naples*
- 16.45-18.30 Selected Oral Communications (Liver failure, hepatobiliary surgery, and transplantation)**
Chairpersons: Q. Lai, *L'Aquila*
S. Ginanni Corradini, *Rome*
- 16.45-17.00 Reasons for recipient ineligibility for liver transplantation**
M. Biolato, G. Marrone, C. Tarli, A. Liguori, L. Miele, G.L. Rapaccini, R. Calia, G. Addolorato, F. Pennestri, S. Agnes, A. Gasbarrini, A. Grieco - *Rome*
- 17.00-17.15 Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis**
Q. Lai, U. Cillo, S. Iesari, A. Finkenstedt, M. Rossi, E. Tsochatzis, G. Otto, G.M. Ettorre, G. Tisone, M. Vivarelli, A.W. Avolio, M. Foguene, J. Lerut on behalf of the European Hepatocellular Cancer Liver Transplant Study Group - *Brussels (Belgium), Rome, Padua, Innsbruck (Austria), London (UK), Mainz (Germany), Ancona*
- 17.15-17.30 Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection**
L. Viganò, C. Soldani, A. Lleo, L. Di Tommaso, B. Franceschini, M. Cimino, M. Donadon, G. Torzilli - *Rozzano (MI)*
- 17.30-17.45 Fatty liver susceptibility to preservation injury using static cold storage versus dynamic machine perfusion**
V. Siciliano, C. Berardo, L.G. Di Pasqua, V. Rizzo, B. Mannucci, P. Richelmi, A.C. Croce, A. Ferrigno, M. Vairetti - *Pavia*
- 17.45-18.00 Changes of indications for liver transplantation in the era of direct acting antiviral therapy in Europe**
G. Perricone, R. Viganò, C. Mazzealli, S. De Nicola, P.A. Cortesi, R. Facchetti, V. Karam, R. Adam, L.S. Belli - *Milan, Monza, Paris (France)*
- 18.00-18.15 Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: a multicenter cohort study**
A. Vitale, F.P. Russo, C. Sposito, A. Cucchetti, G. Levi Sandri, S. Gruttadauria, S. Di Sandro, D. Ghinolfi, D. Nicolini, F. Trevisani on behalf of the Special Interest Group on Hepatocellular Carcinoma and new anti-HCV therapies of the Italian Association for the Study of the Liver (AISF) - *Padua, Milan, Bologna, Rome, Palermo, Pisa, Ancona*
- 18.15-18.30 Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: risk factors and outcome**
M. Bartoletti, M. Baldassarre, M. Domenicali, R. Lewis, M. Giannella, M. Rinaldi, M. Tufoni, G. Zaccherini, M. Tamè, S. Berardi, L. Napoli, F.M. Pavarin, F. Angela, F. Trevisani, M. Bernardi, P. Viale, P. Caraceni - *Bologna, Rimini*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

Friday, February 23rd

- 08.30-10.00 Selected Oral Communications
(Hepatitis C, B and delta clinical)**
*Chairpersons: C. Ferrari, Parma
G. Brancaccio, Padua*
- 08.30-08.45 Forecasting liver disease burden**
S. Robbins, L.A. Kondili, S. Blach, I. Gamkrelidze, A.L. Zignego, M.R. Brunetto, G. Raimondo, G. Taliani, A. Iannone, F.P. Russo, T. Santantonio, M. Zuin, L. Chessa, P.L. Blanc, M. Puoti, M. Vinci, E.M. Erne, M. Strazzabosco, M. Massari, P. Lampertico, M.G. Rumi, A. Federico, C. Ferrari, A. Ciancio, G. Borgia, P. Andreone, N. Caporaso, M. Persico, D. Ieluzzi, A. Gori, A. Gasbarrini, C. Coppola, S. Madonia, G.B. Gaeta, A. Andriulli, S. Montilla, H. Razavi, M. Melazzini, S. Vella, A. Craxì on behalf of PITER collaborating group *Lafayette (CO, USA), Rome, Florence, Pisa, Messina, Bari, Padua, Foggia, Milan, Cagliari, Monza, Reggio Emilia, Naples, Parma, Turin, Bologna, Salerno, Verona, San Giovanni Rotondo (FG), Palermo*
- 08.45-09.00 Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment**
M. Iavarone, A. Loglio, G. Grossi, M. Viganò, F. Facchetti, M.G. Rumi, A. Sangiovanni, P. Lampertico - *Milan*
- 09.00-09.15 Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection**
G.P. Caviglia, A. Olivero, A. Ciancio, F. Tandoi, G. Troshina, C. Bosco, L. Boglione, M. Rizzetto, R. Romagnoli, G.M. Saracco, A. Smedile - *Turin*
- 09.15-09.30 IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: a multicenter prospective trial in Italy**
A. Sangiovanni, E. Alimenti, M. Barone, L.S. Belli, E. Biganzoli, G. Borgia, M. Brunacci, M.R. Brunetto, R. D'Ambrosio, S. Fargion, R. Filomia, M. Gambato, R. Gattai, E.G. Giannini, S. Maimone, L. Marzi, F. Oliveri, G. Pellegatta, G. Raimondo, M. Rumi, F.P. Russo, I. Serio, N.M. Terreni, L. Valenti, E. Villa, P. Lampertico - *Milan, Naples, Genoa, Pisa, Messina, Padua, Bologna, Como, Modena, Bari*
- 09.30-09.45 Combination of HBV serological markers can predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg-negative Chronic Hepatitis B Infection**
R. Salpini, L. Colagrossi, U.S. Gill, A. Battisti, L. Piermatteo, N. Hansi, C.F. Perno, P.T.F. Kennedy, V. Svicher - *Rome, London (UK), Milan*
- 09.45-10.00 Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): a report from the Lombardy Network**
R. D'Ambrosio, L. Pasulo, A. Aghemo, M. Puoti, S. Zaltron, F. Maggiolo, G. Rizzardini, S. Fargion, P. Sacchi, R. Gulminetti, M. Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A. Rossini, A. Corbellini, C. Uberti Foppa, A. Colli, P. Lampertico, S. Fagioli on behalf of the NAVIGATOR II study group - *Milan, Rozzano (MI), Brescia, Bergamo, Pavia, Varese, Cremona, Vizzolo Predabissi (MI), Lecco*
- 10.00-10.30 State-of-the-Art Lecture**
Introduced by: N. Caporaso, Naples
Access to medicines in liver disease: what have learned?
S. Vella, *Rome*
- 10.30-11.00 Coffee break and Posters view**
*Tutors: P. Dongiovanni, Milan
F.R. Ponziani, Rome*
- 11.00-12.20 Symposium "Hepatology and Gender"**
*Chairpersons: D. Alvaro, Rome
E. Villa, Modena*
- 11.00-11.20 Obesity and liver cancer: gender influence?**
E. Vanni, *Turin*
- 11.20-11.40 HCC, HCV, DAAs and gender impact**
M. Gambato, *Padua*
- 11.40-12.00 Gender, waiting list, transplantation and outcome** - P. Toniutto, *Udine*
- 12.00-12.20 Discussion**
- 12.20-13.35 Selected Oral Communications
(Hepatocellular carcinoma clinical and experimental)**
*Chairpersons: L. Viganò, Milan
F. Piscaglia, Bologna*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- 12.20-12.35 **Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib**
G. Antonelli, E. Gigante, M. Iavarone, P. Begini, A. Sangiovanni, E. Iannicelli, P. Biondetti, A. Pellicelli, L. Miglioresi, P. Marchetti, P. Lampertico, M. Marignani
Rome, Milan
- 12.35-12.50 **Clinical significance of time related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma**
G. Ricco, C. Cosma, G. Bedogni, A. Biasiolo, M. Guarino, P. Pontisso, F. Morisco, F. Oliveri, D. Cavallone, F. Bonino, M. Plebani, M.R. Brunetto - *Pisa, Padua, Trieste, Naples, Chianciano Terme (SI)*
- 12.50-13.05 **Pathobiological and radiomic approach for hepatocellular carcinoma subclassification**
F. Vasuri, M. Renzulli, S. Fittipaldi, L. Bolondi, R. Golfieri, A. D'Errico - *Bologna*
- 13.05-13.20 **Loss of hepatic RuvBL1 accelerates DEN-induced carcinogenesis due to chronic liver damage and regeneration**
M. Materozzi, F. Zanieri, E. Ceni, S. Polvani, M. Tarocchi, O. Bereshchenko, A. Galli, T. Mello - *Florence, Siena, Perugia*
- 13.20-13.35 **Functional characterization of a novel genetic variant predisposing to hepatocellular carcinoma development in nonalcoholic fatty liver disease**
G.A. Baselli, M. Longo, M. Meroni, S. Pelusi, A.L. Fracanzani, G. Soardo, E. Bugianesi, R. Romagnoli, S. Petta, L. Miele, R. De Francesco, S. Fargion, P. Dongiovanni, L. Valenti - *Milan, Turin, Palermo, Rome*
- 13.35-14.35 **Lunch break and Posters view**
Tutors: M. Gambato, *Padua*
F. Pezzuto, *Naples*
- 14.35-15.35 **General Assembly III**
- 15.35-15.50 **Presentation of the AISF distinguished service award to Prof. Antonio Craxi**
Introduced by: G. Raimondo, *Messina*
- 15.50-17.20 **Selected Oral Communications (NAFLD/ALD clinical and experimental)**
Chairpersons: M. Masarone, *Naples*
F. Marra, *Florence*
- 15.50-16.05 **Modulation of the NLRP3 inflammasome pathway mediates the anti-inflammatory action of indoleamine dioxygenase in experimental NASH**
E. Vivoli, B. Piombanti, F. Marra - *Florence*
- 16.05-16.20 **Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD**
C. Rosso, R. Younes, M. Eslam, F.W. Chen, M. Cucco, M. Gaggini, S. Coulter, F. Carli, C. Barbieri, V. della Latta, M.L. Abate, G.M. Saracco, A. Gastaldelli, J. George, E. Bugianesi - *Turin, Sydney (Australia), Pisa*
- 16.20-16.35 **Berberis Aristata, Elaeis Guineensis and Coffea Canephora extracts modulates the microRNA-122 expression and improves hepatic steatosis in mice fed high fat diet**
V. Lembo, P. Mirra, G. Mazzone, A. Rossi, G. D'Argenio, V. Cossiga, C. Nigro, C. Miele, F. Beguinot, N. Caporaso, F. Morisco - *Naples*
- 16.35-16.50 **Metabolomics in the progression of non alcoholic fatty liver disease**
J. Troisi, M. Masarone, A. Aglitti, C. Di Zenzo, V. Rosato, M. Persico - *Salerno*
- 16.50-17.05 **Role of SERPINB3 like serological and molecular biomarker into NASH development and progression**
S. Maier, S.L. Crocè, M.R. Buonocore, C. Pilon, S. Fargion, R. Vettor, L.A. Sechi, D. Donnini, C. Pagano, L. Valenti, G. Soardo
Udine, Trieste, Padua, Milan
- 17.05-17.20 **Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with Non-Alcoholic Fatty Liver Disease**
P. Dongiovanni, M. Meroni, A. Cespiati, G.A. Baselli, R. Rametta, S. Pelusi, A. Fracanzani, S. Badiali, J. Pihlajamaki, S. Romeo, S. Petta, A. Craxi, V. Nobili, S. Fargion, L. Valenti - *Milan, Kuopio (Finland), Gothenburg (Sweden), Palermo, Rome*
- 17.20-17.35 **Young Investigators Awards**
Presenters for the 2 best oral communications
Basic: C. Balsano, *Rome*
Clinical: G. Squadrito, *Messina*
Presenters for the 2 best posters
Basic: F. Pezzuto, *Naples*
P. Dongiovanni, *Milan*
Clinical: F.R. Ponziani, *Rome*
M. Gambato, *Padua*
- 17.35 **Closure of the Annual Meeting**



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

Poster Session Thursday, February 21st

- N° 1 The course of oesophago-gastric varices in patients with cirrhosis after DAA-induced HCV clearance**
V. Calvaruso, I. Cacciola, S. Petta, G. Caccamo, E. Conte, M. G. Minissale, M. Licata, F. Simone, G. Squadrito, A. Licata, G. Raimondo, A. Craxi, V. Di Marco - *Palermo, Messina*
- N° 2 HCV eradication by DAA improves glucose tolerance and reduces post-load insulin resistance in cirrhotic patients with genotype 1**
F. Salomone, M. Catania, G. Bertino, J. Godos, G. Magri, G. Li Volti, A. Montineri - *Catania*
- N° 3 Pre-treatment risk stratification in primary biliary cholangitis: a predictive model to guide first-line combination therapy**
M. Carbone, A. Nardi, G. Carpino, V. Cardinale, H. Ainsworth, M. Heneghan, D. Thorburn, A. Bathgate, R. Jones, J.M. Neuberger, P.M. Battezzati, M. Zuin, S. Taylor-Robinson, M. Donato, J. Kirby, R. Mitchell-Thain, A. Floreani, F. Sampaziotis, L. Muratori, D. Alvaro, M. Marzoni, L. Miele, F. Marra, E. Giannini, E. Gaudio, V. Ronca, G. Bonato, L. Cristoferi, F. Malinverno, A. Gerussi, H.J. Cordell, G.M. Hirschfield, D. Stocken, G.J. Alexander, R.N. Sandford, D.E. Jones, P. Invernizzi, G.F. Mells for the Italian PBC Study Group & UK-PBC Consortium *Cambridge (UK), Milan, Rome, Newcastle (UK), London (UK), Edinburgh (UK), Leeds (UK), Birmingham (UK), Padua, Bologna, Ancona, Florence, Genoa*
- N° 4 The cancerogenic potential of primary human Cholangiorcinoma cells is inhibited by Obeticholic Acid, a Farnesoid X Receptor (FXR) agonist**
S. Di Matteo, L. Nevi, D. Costantini, M. Colantonio, F. Giulitti, C. Napoletano, S. Safarikia, E. Manzi, A. M. Derose, F. Melandro, M.C. Bragazzi, G. Grazi, P.B. Berloco, F. Giuliani, G. Carpino, V. Cardinale, E. Gaudio, D. Alvaro - *Rome*
- N° 5 Adherence to EASL antibiotic treatment recommendations improves the outcomes of patients with cirrhosis and bacterial infections. Results from the ICA "Global Study"**
S. Piano, V. Singh, P. Caraceni, R. Maiwall, C. Alessandria, J. Fernandez, E.C. Soares, D.J. Kim, S.E. Kim, M. Marino, J. Vorobioff, R. Ribeiro Barea, M. Merli, L. Elkrief, V. Vargas, A. Krag, S.P. Singh, L.A. Lesmana, C. Toledo, S. Marciano, X. Verhelst, F. Wong, N. Intagliata, L. Rabinowich, L.A. Colombato, S.G. Kim, A. Gerbes, F. Durand, J.P. Roblero, K.R. Bhamidimarri, T.D. Boyer, M. Maevskaya, E. Fassio, H.S. Kim, J.S. Hwang, A. Gadano, S.K. Sarin, P. Angeli on behalf of the International Club of Ascites Global Study Group - *Padua, Chandigarh (India), Bologna, New Delhi (India), Turin, Barcelona (Spain), Campinas (Brazil), Chuncheon (Republic of Korea), Anyang (Republic of Korea), Buenos Aires (Argentina), Rosario (Argentina), Campo Grande (Brazil), Rome, Geneva (Switzerland), Odense (Denmark), Cuttack (India), Jakarta (Indonesia), Valdivia (Chile), Buenos Aires (Argentina), Ghent (Belgium), Toronto (Canada), Charlottesville (VA,USA), Tel-Aviv (Israel), Bucheon (Republic of Korea), Munich (Germany), Clichy (France), Santiago (Chile), Miami (FL,USA), Tucson (AZ, USA), Moscow (Russia), Seoul (Republic of Korea), Daegu (Korea)*
- N° 6 The inhibitory effect of ADM on hepatic NF-kB activation in 2D and 3D hepatic cell cultures**
S. De Martin, E. Caon, D. Gabbia, A. Floreani, G. Zigiotta, Z. Zhang, L. Frenguelli, W. Al-Akkad, S. Sarcognato, M. Guido, G. Mazza, M. Pinzani, K. Rombouts - *Padua, London (UK)*
- N° 7 Hepatic ischemic injury decreases using negative allosteric modulators of metabotropic glutamate receptor subtype 5**
C. Berardo, V. Siciliano, L.G. Di Pasqua, P. Richelmi, F. Nicoletti, M. Vairetti, A. Ferrigno - *Pavia, Rome*
- N° 8 Establishment of expanding 3D-organoids cultures from human fetal biliary tree stem cells (hBTSCs) as a potential tool for regenerative medicine and disease modeling**
S. Safarikia, V. Cardinale, G. Carpino, D. Costantini, S. Di Matteo, L. Nevi, D. Bosco, E. Gaudio, D. Alvaro - *Rome*
- N° 9 Impact of Neuromedin-B receptor variants on iron overload disorders**
R. Rametta, G. Baselli, P. Dongiovanni, S. Pelusi, M. Meroni, A.L. Fracanzani, S. Fargion, L. Valenti - *Milan*
- N° 10 Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with Primary Biliary Cholangitis**
P. Andreone, A. Floreani, P. Invernizzi, G. Mazzella, J. Owens-Grillo, E. Smoot Malecha, L. MacConell - *Bologna, Padua, Milan, San Diego (CA, USA)*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- N° 11 A worldwide cross-ethnic study of quality of life in patients with PBC: attitude or latitude?**
M. Carbone, L. Montali, A. Gragnano, M. Miglioretti, A. Frigerio, M. Yagi, F. Malinverno, F. Bernuzzi, L. Jopson, A. Reig, S. Pilar, the Japanese PBC Study Group, the UK-PBC Study Group, A. Pares, A. Tanaka, G.F. Mells, D.E. Jones, P. Invernizzi - *Milan, Tokyo (Japan & the Japanese PBC), Barcelona (Spain), Cambridge (UK), Newcastle upon Tyne (UK)*
- N° 12 HBV reservoir and enhanced cccDNA transcriptional activity in HBeAg negative chronic hepatitis B**
L. Colagrossi, R. Salpini, U.S. Gill, A. Battisti, L. Piermatteo, D. Di Carlo, N. Hansi, F. Ceccherini-Silberstein, C.F. Perno, P.T.F. Kennedy, V. Svirch - *Rome, London (UK), Milan*
- N° 13 Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study**
G.G. Di Costanzo, C.K.Y. Ng, N. Tosti, R. Tortora, V. Paradiso, M. Coto-Llerena, G. Roscigno, V. Perrina, C. Quintavalle, T. Boldanova, S. Wieland, G. Marino-Marsilia, M. Lanzafame, L. Quagliata, G. Condorelli, M.S. Matter, M.H. Heim, M. Guarracino, L.M. Terracciano, S. Piscuoglio - *Naples, Basel (Switzerland)*
- N° 14 Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease**
S. Pelusi, G. Baselli, A. Pietrelli, P. Dongiovanni, M. Meroni, B. Donati, A.L. Fracanzani, R. Romagnoli, S. Petta, L. Miele, A. Grieco, E. Bugianesi, G. Soardo, R. De Francesco, S. Fargion, L. Valenti - *Milan, Turin, Palermo, Rome, Udine*
- N° 15 Role of the protein tyrosine kinase Mer (MerTK) in the cross-talk between macrophages and hepatic stellate cells**
M. Pastore, G. Di Maira, A. Caligiuri, S. Petta, F. Marra - *Florence, Palermo*
- N° 16 Incomplete normalization of transaminases at 18 months is the most important predictor for failure of biochemical response in autoimmune hepatitis**
A. Gerussi, N. Halliday, D. Roccarina, F. Saffioti, P. Polly, A. Marshall, D. Thorburn - *London (UK), Udine, Messina*
- N° 17 Characterization of HBV integration landscape in tumor and non-tumor liver tissues by a high-throughput viral integration detection method**
D. D'Aliberti, D. Giosa, G. Raffa, C. Musolino, G. Tripodi, D. Lombardo, F. Casuscelli di Tocco, C. Saitta, O. Romeo, G. Navarra, G. Raimondo, T. Pollicino - *Messina*
- N° 18 Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study**
E. Degaspero, G. Tosetti, R. D'Ambrosio, A. Aghemo, M. Borghi, R. Soffredini, M. Primignani, P. Lampertico - *Milan, Rozzano (MI)*
- N° 19 The exposure of primary cultures of human biliary tree stem/progenitor cells (hBTSCs) to different micro-environmental factors induces proliferation, epithelial-mesenchymal transition (EMT) and senescence, which are typical pathological features of human cholangiopathies**
D. Costantini, V. Cardinale, G. Carpino, L. Nevi, S. Di Matteo, S. Safarikia, F. Melandro, P. Berloco, E. Gaudio, D. Alvaro - *Rome*
- N° 20 Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Advanced Fibrosis/Compensated Cirrhosis**
S. Petta, L.E. Adinolfi, A.L. Fracanzani, V. Calvaruso, F. Rini, C. Cammà, V. Di Marco, A. Marrone, R. Nevola, A. Pinto, L. Rinaldi, D. Torres, A. Tuttolomondo, L. Valenti, S. Fargion, A. Craxì - *Palermo, Naples, Milan*
- N° 21 Health-economic evaluation of different organizational models to manage the Hepatitis C patient journey**
S. Fagioli, L. Pasulo, F. Maggiolo, R. Spinella, P. Del Poggio, R. Boldizzoni, M. Di Marco, A. Aronica, C. Benedetti, P. Correale, C. Garavaglia, C. Nicora - *Bergamo, Treviglio (BG), Seriate (BG), Milan*
- N° 22 Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: the NAVIGATOR Lombardia-Veneto network**
F. Invernizzi, L. Pasulo, A. Aghemo, M. Puoti, S. Zaltron, F. Maggiolo, G. Rizzardini, S. Fargion, P. Sacchi, R. Gulminetti, M. Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A. Rossini, A. Corbellini, C. Uberti Foppa, L. Belli, S. Piovesan, P. Angeli, L. Chemello, F.P. Russo, P. Burra, V. Vincenzi, A.M. Cattelan, G. Carolo, F. Capra, G. Carlotto, P.A. Rovere, S. Lobello, P. Scotton, S. Panese, P. Fabris, A. Alberti, P. Lampertico, S. Fagioli on behalf of the NAVIGATOR study group - *Milan, Bergamo, Rozzano (MI), Brescia, Pavia, Varese, Cremona, Vizzolo Predabissi (MI), Padua, Belluno, Verona, Treviso, Venezia, Vicenza*
- N° 23 IL28 polymorphism and HCC after DAAs for chronic hepatitis C**
A. Simili, G. Mazzella, F. Ravaioli, F. Davide, M.L. Bacchi-Reggiani, A. Porro, F. Bazzoli, F. Azzaroli - *Bologna*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- N° 24 Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE Mylab: the CLEVER Study**
F. Piscaglia, A. Berzigotti, I. Amat-Roldan, V. Sansone, H. Stefanescu, B. Procopet, I. Bilbao-Areste, G. Allegretti, S. Lens, J.C. Garcia-Pagan, C. Di Bonaventura, F. Ravaioli, L. Mulazzani, R. Golfieri, R. Vukotic, J. Bosch on behalf of the CLEVER Study investigators - *Bologna, Bern (Switzerland), Barcelona (Spain), Cluj Napoca (Romania)*
- N° 25 A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond**
A. Colecchia, F. Ravaioli, G. Marasco, A. Colli, E. Dajti, A. Di Biase, M.L. Bacchi Reggiani, A. Berzigotti, M. Pinzani, D. Festi - *Bologna, Modena, Bern (Switzerland), Verona, Lecco, London (UK)*
- N° 26 Natural killer cell trafficking dysfunction in hepatocellular carcinoma**
G. Missale, C. Carone, D. Canetti, V. Regina, V. Capizzuto, A. Olivani, R. Dalla Valle, C. Ferrari, E. Cariani - *Parma, Modena*
- N° 27 SVR is the strongest predictor of Occurrence and Recurrence of Hepatocellular Carcinoma in HCV Cirrhotic Patients after treatment with Direct Acting Antivirals: a prospective multicenter Italian study**
A. Lleo, A. Aglitti, A. Ciancio, V. Di Marco, A. Aghemo, P. Lampertico, M.R. Brunetto, M. Zuin, P. Andreone, E. Villa, G. Troshina, V. Calvaruso, E. Degaspero, B. Coco, A.M. Giorgini, F. Conti, A. Di Leo, L. Marzi, V. Boccaccio, S. Bollani, P. Maisonneuve, M. Rendina, M. Persico, S. Bruno - *Rozzano (MI), Milan, Salerno, Turin, Palermo, Pisa, Bologna, Modena, Bari*
- N° 28 Assessing the risk of de novo neoplasms after liver transplantation: role of pre-transplant hepatocellular carcinoma**
S. Shalaby, M. Taborelli, A. Zanetto, A. Ferrarese, C. Becchetti, S.S. Sciarrone, M. Gambato, G. Germani, M. Senzolo, F.P. Russo, G. Zanus, U. Cillo, P. Piselli, D. Serraino, P. Burra - *Padua, Aviano (PN), Rome*
- N° 29 Shear wave elastography to assess spleen stiffness: its feasibility and reproducibility in patients with chronic liver disease and its utility in the prediction of portal hypertension**
C.B. Conti, M. Giunta, G. Casazza, D. Gridavilla, V. La Mura, G. Tosetti, A. Nicolini, M. Primignani, D. Conte, M. Vecchi, M. Fraquelli - *Milan*
- N° 30 Is stiffness reliable for the detection of liver fibrosis in HCV patients treated with direct acting antiviral drugs (DAAs)? A prospective cohort study**
S. Gaia, E. Vanni, D. Campion, E. Rolle, D. Stradella, P. Cortegoso Valdivia, A. Evangelista, A. Ciancio, A. Smedile, R. Trapani, G.M. Saracco - *Turin*
- N° 31 Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3-year study**
R. D'Ambrosio, E. Degaspero, M. Iavarone, A. Sangiovanni, A. Aghemo, R. Soffredini, M. Borghi, R. Perbellini, G. Lunghi, P. Lampertico - *Milan*
- N° 32 Progressive reduction of blood lysosomal acid lipase activity according to stage of adult chronic liver disease and altered enzymatic cellular distribution in cirrhosis**
I. Mignini, M. Mischitelli, F. Angelico, A. De Santis, M.L. Attilia, F. Baratta, F. Ferri, D. Pastori, M. Del Ben, M. Pellone, S. Parisse, F. Piemonte, G. Tozzi, J. D'Amico, F. Violi, S. Ginanni Corradini - *Rome*
- N° 33 Fibroscan liver stiffness (LMS) and controlled attenuation parameter (CAP) in the evaluation of cardiovascular risk assessment in patients with NAFLD**
R. Lombardi, S. Petta, A. Giannetti, R. Boemi, G. Pisano, C. Bertelli, A. Craxi, S. Fargion, A.L. Fracanzani - *Milan, Palermo*
- N° 34 Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: analysis of 3345 patients from the Lombardia Network**
E. Degaspero, L. Pasulo, A. Aghemo, M. Puoti, S. Zaltron, F. Maggiolo, G. Rizzardini, S. Fargion, P. Sacchi, R. Gulminetti, M. Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A. Rossini, A. Corbellini, C. Uberti Foppa, A. Colli, P. Lampertico, S. Fagioli on behalf of the NAVIGATOR II study group - *Milan, Rozzano (MI), Bergamo, Pavia, Varese, Cremona, Brescia, Vizzolo Predabissi (MI), Lecco*
- N° 35 Filamin a expression predicts early recurrence of hepatocellular carcinoma after hepatectomy**
M. Donadon, L. Di Tommaso, C. Soldani, B. Franceschini, E. Vitali, M. Roncalli, A. Lleo, A. Lania, G. Torzilli - *Rozzano (MI)*
- N° 36 Prognostic role of BAP1 and PBRM1 expression in intrahepatic cholangiocarcinoma**
S. Sarcognato, E. Gringeri, M. Fasan, M. Di Giunta, V. Guzzardo, U. Cillo, M. Guido - *Padua*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

N° 37 Pattern of hepatocarcinoma recurrence in cirrhosis: the role of anatomic and parenchyma-sparing resection. A propensity score analysis

S. Famularo, S. Di Sandro, A. Giani, A. Lauterio, F. Romano, V. Buscemi, F. Uggeri, R. De Carlis, L. Gianotti, L. De Carlis - *Milan, Monza*

N° 38 Serum and bile squamous cell carcinoma antigen detection: a new prognostic marker in patients with perihilar cholangiocarcinoma

E. Gringeri, M. Di Giunta, A. Biasiolo, M. Ruvoletto, G. Villano, L. Zarantonello, P. Pontisso, U. Cillo - *Padua*

N° 39 Use of a new type of controlled expansion stent in the creation of Transjugular Intrahepatic Portosystemic Shunt for the treatment of severe portal hypertension. A single center experience with 1 year follow-up

I. Petridis, A. D'Antoni, G. Pietrosi, L. Maruzzelli, R. Miraglia, A. Luca R. Volpes - *Palermo*

N° 40 Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: a single-center experience

R. D'Ambrosio, E. Degaspero, A. Aghemo, M. Borghi, R. Perbellini, S. De Nicola, G. Lunghi, P. Lampertico - *Milan*

Poster Session

Friday, February 23rd

N° 1 Low levels of Squamous Cell Carcinoma Antigen-IgM complexes in serum are predictors of better survival in patients with liver cirrhosis

M. Cagnin, A. Biasiolo, A. Gallotta, A. Martini, M. Ruvoletto, S. Quarta, S. Fasolato, P. Angeli, G. Fassina, P. Pontisso - *Padua, Venice*

N° 2 Primary Biliary Cholangitis (PBC): the patient journey to diagnosis and through the disease

A. Floreani, B. Marini, S. Provisone, C. Bassanelli, E. De Santis, N. Cazzagon, M. Margotti, P. Andreone, L. Muratori, P. Invernizzi, M. Marziani, A. Benedetti, D. Alvaro, V. Calvaruso, A. Craxi - *Padua, Milan, Bologna, Ancona, Rome, Palermo*

N° 3 Acquisition of stem-like features in human cholangiocarcinoma is associated with an oxidative glucose metabolism

C. Raggi, N. Navari, M.L. Taddei, E. Sacco, M. Correnti, I. Orlandi, P. Chiarugi, F. Marra - *Florence, Milan, Rozzano (MI)*

N° 4 Extracellular signal-regulated kinase 5 (ERK5) regulates growth, migration and invasion of cholangiocarcinoma (CCA) cells

A. Gentilini, A. Caligiuri, G. Di Maira, M. Pastore, E. Rovida, F. Marra - *Florence*

N° 5 The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE)

C. Campani, A. Vitale, G. Dragoni, S. Aburas, U. Arena, E.G. Giannini, F. Trevisani, F. Marra for the Ita.Li.Ca. study group - *Florence, Padua, Genoa, Bologna*

N° 6 Influence of DAA treatment on waitlisting and transplant rate for HCV related disease: preliminary results of a single center experience

C. Iegri, L. Pasulo, M. Colpani, F. Leonardi, M. Colledan, M.G. Lucà, N. Pinelli, A. Ghirardi, S. Fagioli - *Bergamo*

N° 7 Microwave ablation and salvage transplantation for patients with hepatocellular carcinoma

A. Bertacco, A. Vitale, M. Di Giunta, E. Fasolo, M. Polacco, R. Boetto, D. Bassi, U. Cillo - *Padua*

N° 8 Multimodal and sequential treatment for hepatocellular carcinoma: how "real-life" complies with international recommendations

M. Triolo, A. Sangiovanni, M. Iavarone, L.V. Forzenigo, A. Nicolini, G. Rossi, V. La Mura, M. Colombo, P. Lampertico - *Milan, Rozzano (MI)*

N° 9 Temporal trends of access to DAAs treatments for HCV in the Navigatore-Lombardia network: evolution of AIFA criteria, DAA regimens and patient features

L. Pasulo, A. Aghemo, G. Rizzardini, R. Rossotti, M. Vinci, A. Spinetti, G. Filice, P. Grossi, A. Ciaccio, M. Colombo, P. Lampertico, S. Fagioli on behalf of the NAVIGATOR-L Study group (L.S. Belli, R. Bruno, S. Bruno, E. Buscarini, I. Carderi, A. Ciaccio, A. Colli, G. Colloredo, A.E. Colombo, M. Colpani, A. Corbellini, A. D'Arminio Monforte, P. Del Poggio, M. Di Marco, L. Fugazza, A. Gori, P. Ghiringhelli, M. Graffeo, R. Gulminetti, P. Invernizzi, S. Lazzaroni, A. Lleo, G. Lorini, F. Maggiolo, B. Menzaghi, L. Minoli, L. Morini, B. Omazzi, A. Pan, B. Paris, G. Perboni, M.G. Pigozzi, L. Pusterla, T. Quirino, T. Re, M. Rumi, P. Sacchi, D. Somaschini, M. Soncini, A. Soria, A.



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

- Spinetti, G. Spinzi, M. Strazzabosco, P. Tau, N. Terreni, M. Tinelli, R. Turrini, C. Uberti Foppa, P. Viganò, M. Vinci, M. Zuin) - *Bergamo, Rozzano (MI), Milan, Brescia, Pavia, Varese, Monza*
- N° 10 Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy**
S. Barbaliscia, V.C. Di Maio, E. Teti, I. Lenci, M. Aragri, E. Polilli, G. Fiorentino, V. Pace Palitti, B. Bruzzone, S. Paolucci, N. Coppola, T. Ruggiero, T. Pollicino, F. Niero, V. Micheli, L.A. Nicolini, S. Marengo, A. Bertoli, I. Maida, S. Francioso, L. Foroghi, V. Calvaruso, F. Morisco, A. Lleo, V. Boccaccio, A. Ciancio, R. Maserati, M. Puoti, M. Zazzi, B. Rossetti, V. Vullo, A.R. D'Ambrosio, L. Boglione, S. Bonora, S. Babudieri, G. Gubertini, M. Rendina, A. Pellicelli, V. Sangiovanni, A. Ciaccio, G. Taliani, G. Raimondo, G.B. Gaeta, A. Craxì, C. Pasquazzi, L. Sarmati, G. Parruti, M. Angelico, M. Andreoni, V. Cento, C.F. Perno, F. Ceccherini-Silberstein on behalf of HCV Virology Italian Resistance Network (Vironet C) - *Rome, Pescara, Genoa, Pavia, Naples, Turin, Messina, Milan, Sassari, Palermo, Rozzano (MI), Siena, Bari*
- N° 11 The protease-inhibitor serpinB3 outlines a stem-like subset in human cholangiocarcinoma**
C. Raggi, A. Cappon, M. Correnti, J.B. Andersen, E. Forti, G. Cavalloni, E. Torchio, P. Pontisso, F. Marra - *Florence, Padua, Rozzano (MI), Copenhagen (Denmark), Candiolo (TO)*
- N° 12 Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease**
L. Mulazzani, V. Sansone, A. Berzigotti, H. Stefanescu, G. Allegretti, F. Ravaioli, G. Marasco, C. Di Bonaventura, C. Serra, R. Vukotic, L. Bolondi, J. Bosch, F. Piscaglia on behalf of the CLEVER Study investigators - *Bologna, Bern (Switzerland), Barcelona (Spain), Cluj Napoca (Romania)*
- N° 13 Insuline resistance improvement after effective Hepatitis C virus eradication and its role on the onset of complications of advanced liver disease**
I. Bortoluzzi, E. Franceschet, M. Gambato, A. Zanetto, A. Ferrarese, S.S. Sciarrone, F. Farinati, P. Burra, A. Mega, F.P. Russo - *Padua, Bolzano*
- N° 14 Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: safety and survival**
F. Invernizzi, M. Iavarone, M.F. Donato, A. Sangiovanni, S. Monico, M.A. Manini, U. Maggi, B. Antonelli, D. Dondossola, G. Rossi, P. Lampertico - *Milan*
- N° 15 Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment**
A. Sangiovanni, R. D'Ambrosio, G. Lunghi, M. Bruccoleri, E. Alimenti, M. Borghi, R. Perbellini, A. Aghemo, M. Iavarone, M. Colombo, P. Lampertico - *Milan, Rozzano (MI)*
- N° 16 HCC recurrence after DAA treatment in HCV patients**
M. Guarino, D. Bruzzone, G.G. Di Costanzo, M. Guarracino, F. Morando, L. Rinaldi, M. Persico, A. Salomone Megna, N. Coppola, N. Caporaso, F. Morisco - *Naples, Salerno, Benevento*
- N° 17 Immune inflammation indicators and ALBI score to predict occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals**
A. Casadei Gardini, F.G. Foschi, F. Conti, E. Petracci, G. Marisi, F. Buonfiglioli, M. Ravaioli, G. Mazzella, P. Muratori, M. Lenzi, C. Crespi, L. Bolondi, L. Badia, G. Verucchi, G. Vitale, R. Vukotic, S. Brillanti, P. Andreone - *Meldola (FC), Faenza (RA), Forlì (FC)*
- N° 18 Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years**
A. Loglio, E. Galmozzi, M. Iavarone, G. Grossi, M. Viganò, F. Facchetti, R. Perbellini, M.G. Rumi, A. Sangiovanni, P. Lampertico - *Milan*
- N° 19 Liver stiffness based model (LSPS) predicts measured portal hypertension (mPH), esophageal varices (EVs) and HCC in patients treated and responsive to DAA for HBV and HCV-related cirrhosis**
A. Tucci, W. Debernardi Venon, M. Pelizza, C. Chialà, A. Ciancio, A. Smedile, G. Saracco, A. Marzano - *Turin*
- N° 20 Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: a report from the Lombardia Network and Navigator Study Group**
E. Degaspero, L. Pasulo, A. Aghemo, M. Puoti, S. Zaltron, F. Maggiolo, G. Rizzardini, S. Fargion, P. Sacchi, R. Gulminetti, M. Zuin, T. Quirino, M.G. Rumi, A. Pan, P. Grossi, A. Rossini, A. Corbellini, C. Uberti Foppa, A. Colli, S. Piovesan, P. Angeli, L. Chemello, F.P. Russo, P. Burra, V. Vincenzi, A.M. Cattelan, G. Carolo, F. Capra, G. Carlotto, P.A. Rovere, S. Lobello, P. Scotton, S. Panese, P. Fabris, A. Alberti, P. Lampertico, S. Fagioli on behalf of the NAVIGATOR study group - *Milan, Rozzano (MI), Brescia, Bergamo, Pavia, Varese, Cremona, Vizzolo*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETÀ
ASSOCIAZIONI
SCIENTIFICHE

Predabissi (MI), Lecco, Padua, Belluno, Verona, Vicenza, Treviso, Venezia

N° 21 HCV clearance and pro-thrombotic shift in advanced liver disease

E. Biliotti, D. Palazzo, R. Cangemi, R. Carnevale, R. Esvan, L. Fontanelli-Sulekova, C. Franchi, P. Maida, C. Nocella, P. Perinelli, M. Santori, M. Spazianta, F. Tamburini, F. Violi, G. Taliani - *Rome, Latina*

N° 22 Galectin-3+ cells in the liver associate with tissue damage in children with NAFLD

N. Panera, F. Oliveira, C. De Stefanis, A. Crudele, V. Nobili, A. Alisi - *Rome, Rio de Janeiro (Brazil)*

N° 23 Monofocal Hepatocellular carcinoma (HCC): is diameter so important? Analysis on the Italian Liver Cancer (ITA.LI.CA) database between BCLC algorithm and Milan criteria

G. Peserico, B. Penzo, F. Pelizzaro, A. Imondi, A. Meneghetti, A. Sartori, M. D'Elia, A. Vitale, F. Trevisani, F. Farinati - *Padua, Bologna*

N° 24 Liver transplant organ allocation; preliminary results using the ISO score system

A. Bertacco, E. Dalla Bona, A. Vitale, M. Di Giunta, M. Polacco, R. Boetto, D. Bassi, U. Cillo - *Padua*

N° 25 Predictors of hepatocellular recurrence after liver transplant in Hepatitis C patients: a ten-years single Center cohort

M. Iavarone, M.F. Donato, F. Invernizzi, M.A. Manini, S. Monico, A. Sangiovanni, M. Maggioni, P. Reggiani, G. Rossi, P. Lampertico - *Milan*

N° 26 Video-laparoscopic MW ablation in a European high volume center: safety and efficacy of 891 procedures

A. Bertacco, A. Vitale, A. Marchini, E. Fasolo, F. D'Amico, E. Gringeri, D. Neri, D. Bassi, R. Carandina, C. Aliberti, U. Cillo - *Padua*

N° 27 Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting

A. Loglio, G. Grossi, R. Soffredini, M. Borghi, F. Facchetti, E. Galmozzi, R. Perbellini, G. Lunghi, P. Lampertico - *Milan*

N° 28 National Quality Control and Validation of Hepatitis C NS3, NS5A and NS5B Genotypic Resistance Testing

T. Ruggiero, V. Cento, M. Aragri, M. Arosio, F. Baldanti, M. Brunetto, B. Bruzzone, E. Boeri, D. Cavallone, N. Coppola, M. Di Stefano, V. Ghisetti, A.P. Callegaro, M.R. Capobianchi, C. Caudai, N. Cuomo, S. Galli, E. Galmozzi, A.R. Garbuglia, W. Gennari, A. Lai, S. Menzo, V. Micheli, C. Minosse, L. Monno, S. Paolucci, T. Pollicino, A. Raddi, G. Raffa, G. Raimondo, M. Sanguinetti, M. Sampaolo, R. Santangelo, T. Santantonio, S. Soldini, M. Starace,

M.L. Vatteroni, A. Craxì, C.F. Perno, F. Ceccherini-Silberstein, M. Zazzi on behalf of HCV Virology Italian Resistance Network (VIRONET C) *Turin, Rome, Bergamo, Pavia, Pisa, Genoa, Milan, Naples, Foggia, Siena, Bologna, Modena, Ancona, Bari, Messina, Palermo*

N° 29 Right timing for transient elastography lead the right follow up after HCV treatment

L. Scribano, D. Caroli, E. Rosa Rizzotto, L. Peraro, D. Martines, F. De Lazzari, S. Lobello - *Padua*

N° 30 Oleuropein and copper: new perspectives against liver disease

C. Balsano, C. Porcu, S. Sideri, S. Tavolaro - *L'Aquila*

N° 31 Liver function tests do not predict liver damage in diabetes. Analysis of liver steatosis and fibrosis by transient elastography in routine diabetes care

R. Lombardi, L. Airaghi, V. Borroni, C. Bertelli, L. Burdick, E. Fatta, F. Iuculano, S. Pelusi, L. Valenti, S. Fargion, A.L. Fracanzani - *Milan*

N° 32 Primary Biliary Cholangitis (PBC): the emotional perception of the disease journey from a patient's perspective

D. Alvaro, B. Marini, C. Bassanelli, E. Coretti, N. Cazzagon, M. Margotti, P. Andreone, L. Muratori, V. Calvaruso, P. Invernizzi, M. Marzoni, A. Benedetti, A. Craxì, A. Floreani - *Rome, Milan, Padua, Bologna, Palermo, Ancona*

N° 33 Technical assessment and reliability of controlled attenuation parameter (CAP) with M probe in NAFLD

A. Salmi, P. Campagnola, C. Ferrari, L. Frulloni - *Brescia*

N° 34 HCV-FiS (HEpatitis C Virus Finger-stick Study): HCV RNA point-of-care testing by GeneXpert in the setting of DAA therapy

F. Bronte, V. Calvaruso, D. Ferraro, S. Petta, B. Magro, V. Di Marco, A. Craxì - *Palermo*

N° 35 Role of nutritional intake on clinical presentation of lean and overweight NAFLD

G. Pisano, R. Lombardi, S. Spreafico, F. Iuculano, E. Fatta, V. Borroni, M. Porzio, S. Pelusi, L. Valenti, S. Fargion, A.L. Fracanzani - *Milan*

N° 36 Screening of esophagogastric varices: performance of the "Expanded Baveno VI criteria" and the "platelet 150/MELD 6" strategy in all etiology compensated advanced chronic liver disease

G. Tosetti, V. La Mura, R. D'Ambrosio, E. Degasperis, N. Mezzina, M. Viganò, M. Rumi, A.L. Fracanzani, R. Lombardo, M. Fraquelli, A. Aghemo, P. Lampertico, M. Primignani - *Milan*



AISF

ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

Riconosciuta con D.M. del 7.5.1998, G.U. del 20.6.1998
Iscritta nell'Elenco di cui all'art. 1, comma 353, della Legge 23.12.2005 n. 266, D.P.C.M. 15.4.2011
Iscritta nell'Elenco di cui all'art. 14, comma 1, del D.L. 14.3.2005, n. 35, convertito nella Legge 14.5.2005 n. 80, D.P.C.M. 15.4.2011



PUBLIC AFFAIRS AWARDS

ECCELLENZA 2011

SOCIETA'
ASSOCIAZIONI
SCIENTIFICHE

N° 37 Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D

A. Olivero, G.P. Caviglia, A. Ciancio, C. Bosco, R. Fontana, G.A. Niro, M. Rizzetto, G.M. Saracco, A. Smedile - *Turin, San Giovanni Rotondo (FG)*

N° 38 Direct-acting antiviral therapy immediately after liver transplant in naïve or NS5A-relapser recipients

S. Martini, C. Chialà, F. Calvo, F. Tandoi, D. Patrono, D. Cocchis, A. Ottobrelli, M. Salizzoni, G.M. Saracco, R. Romagnoli - *Turin*

N° 39 Non-invasive evaluation of change in liver fibrosis after viral eradication in patients with HCV related cirrhosis

R. Carrara, A. Ferrarese, E. Franceschet, A. Zanetto, M. Gambato, A. Floreani, F. Farinati, P. Burra, F.P. Russo - *Padua*

N° 40 Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: a single center 3-year study from Italy

F. Invernizzi, M.F. Donato, S. Monico, M. Borghi, D. Dondossola, B. Antonelli, G. Lunghi, R. Perbellini, F. Fabrizi, G. Rossi, P. Lampertico - *Milan*